S&P 5007,561.67▼0.4% Nasdaq25,136.27▼0.9% Dow52,347.55▲0.1% Russell 2K2,790.49▼0.3% 10-Yr5.15%+5bp VIX19.30+0.60 WTI$88.56▼0.2% Gold$3,886.30▲0.0% EUR/USD1.105▼0.4% BTC$65,305▲1.8% Nikkei61,142▲0.5%
At close · Fri, Nov 13, 2026
Daily Market Updates.

US Markets

Home›US Markets›IPOs›The FDA blocked Summit Therapeutics' lung-cancer drug

The FDA blocked Summit Therapeutics' lung-cancer drug

Summit Therapeutics' shares fell 10% following the rejection.

Summit Therapeutics faced a setback when the FDA declined to approve a lung-cancer drug, according to MarketWatch.

The regulator stated the medication must demonstrate its ability to extend patients' lives, adding pressure on the company.

Following the decision, the company's stock dropped sharply, reflecting investor uncertainty.

The market reaction underscores the drug's significance in oncology treatments.

More like this

Sources

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.